Table 1.

Immune checkpoints, their ligands distribution and antibody

Immune checkpoint	Ligand	Distribution of ligand	Antibody	Antibody type	Cancer
CTLA-4	CD80(B7-1) CD86(B7-2)	APCs	Ipilimumab	Human IgG1	Melanoma
PD-1	PD-L1(B7-H1) PD-L2(B7-DC)	Hematopoietic cells Non-hematopoietic cells Tumor cells	Pembrolizumab Nivolumab Atezolizumab	Human IgG4 Human IgG4 Human IgG1	Melanoma NSCLC
LAG-3	MHC-II Galectin-3 LSECtin FGL-1	APCs Tumor cells	GSK2831781	Human IgG	Melanoma Colon adenocarcinoma Ovarian cancer
Tim3	Galectin-9 Phosphatidylserine CEACAM1 HMGB1	Hematopoietic cells Apoptotic cells Tumor cells	TSR-022 LY3321367 MBG453	Human IgG4 Human IgG1 Human IgG4	Liver cancer Solid tumor AML
TIGIT	CD155(PVR) CD112(PVRL2)	APCs, T cells Non-hematopoietic cells, Tumor cells	Tiragolumab AB-154 BMS-986,207	Human IgG1 Human IgG1 Human IgG1	NSCLC Solid tumor